TG THERAPEUTICS INC. - COMMON STOCK

TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

03 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Extension of BLA PDUFA Date for Ublituximab to Treat Patients with RMS

31 May 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

26 May 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

20 May 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference

26 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL

15 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting

06 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting

04 Apr 2022 06:44:26 By Nasdaq GlobeNewswire

TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting

10 Mar 2022 07:15:30 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting

04 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLL

03 Mar 2022 07:00:01 By Nasdaq GlobeNewswire

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results

01 Mar 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

25 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business Update

24 Feb 2022 06:30:01 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference

24 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference

05 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Expands Term Loan Facility With Hercules Capital to $200 Million

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data from the UNITY-CLL Phase 3 Trial Presented at the 63rd American Society of Hematology (ASH) Annual Meeting

14 Dec 2021 06:30:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

14 Dec 2021 06:15:00 By Nasdaq GlobeNewswire

TG Therapeutics Announces Data Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

13 Dec 2021 06:30:00 By Nasdaq GlobeNewswire